Breakfast News: AstraZeneca's Heart Drug Flatlines

Breakfast News: AstraZeneca's Heart Drug Flatlines

July 9, 2026

| Wednesday's Markets | | --- | | S&P 500 7,483 (-0.28%) | | Nasdaq 25,871 (+0.20%) | | Dow 52,348 (-1.09%) | | Bitcoin $62,163 (-2.53%) |

Source: Image created by Jester AI.

1. AZN Sinks as Heart Drug Fails Test Target

**AstraZeneca **(AZN 1.92%) fell over 8% ahead of the opening bell after a late-stage clinical trial for its heart disease drug Wainua failed to meet its target, with the stock down on the potential impact it could have on profitability.

• Wainua "did not provide a statistically significant benefit": The drug is designed to help a condition that affects between 300,000 and 500,000 people globally, and marks the second recent setback for the Team Rule Breakers recommendation following the approval delay from U.S. regulators for a new cancer treatment back in May.
• The drugmaker reported 16 positive late-stage trial results last year: In November, Fool analysts including Asit Sharma, Karl Thiel, and Jason Moser explained the business "wants to get even further ahead," and said there's the "potential for quantum computing and other technological innovation to have a massive positive impact on drug development."

2. Diverging Earnings Reaction From LEVI, PSMT, and AZZ

• Levi Strauss (LEVI 1.18%) dropped around 6% before the market opened despite quarterly revenue and earnings beating expectations, as the full-year revenue guidance increase didn't impress investors enough, with some concern around tariffs and costs going forward.
• PriceSmart (PSMT 1.48%) was little changed ahead of the opening bell following a mixed bag of results. Earnings per share missed consensus, but investor sentiment was boosted with plans for global expansion into Chile.
• AZZ (AZZ 0.31%) popped almost 8% in pre-market trading thanks to results showing high industrial demand for metal coatings. The Team Hidden Gems recommendation also raised the full-year outlook.

3. Fed Minutes Unveil Rate Divisions

The Federal Reserve's June meeting minutes revealed policymakers entertained different scenarios for interest rates going forward, although ambiguity around the competing views meant the immediate impact on the stock market was muted.

• "Participants noted that their future policy actions would depend on incoming information": Voting members noted the risks of higher inflation, but balanced this with the need to monitor the impact of the situation in the Middle East for any easing in energy price disruption.
• 14-page meeting summary shorter than typical release: In line with new Fed Chair Warsh's statement that Fed officials should communicate less about future policy intentions, the meeting minutes were balanced without providing more guidance than previously offered.

4. SK Hynix Draws Giant U.S. ADR Demand

Bloomberg reports the U.S. listing for Korean memory chipmaker SK Hynix is more than seven times oversubscribed, as the offering could be set to rank among the largest ever debuts by a foreign company.

• High institutional demand noted: The listing, via American depositary receipts (ADRs), has attracted a lot of interest from sovereign wealth funds and more traditional asset managers who will be able to get exposure more easily in a U.S. marketplace.
• The offering could raise about $24.5 billion: Based on Bloomberg calculations, the share equivalent of the ADR means the funds raised would rank second only to the $25 billion raised by Alibaba (BABA +11.04%) back in 2014.

5. Today's Take: Credit Where It's Due

I like how Carol Tomé, the CEO of **UPS **(UPS 1.80%), thinks about it. She has said she wants her legacy judged by the leadership team she leaves behind when she retires. Valuations and market cycles are largely outside a CEO's control. The people and culture they build are not.-- Anthony Schiavone

The founder who is responsible for the company's product, brand, and vision is immensely responsible for success. A CEO who creates a new vision and turns a company around is a massive contributor. But there are also cases where a business thrives or survives in spite of its leadership, simply because the product is so important or because the environment is easy to navigate.-- Alicia Alfiere Team Rule Breakers

6. Your Take

Which, if any, positions have you sold all or some of from your portfolio in the last month, and why?

Share with friends and family, or become a member to hear what your fellow Fools are saying!